Trinity's Opsona begins phase II trial for renal transplant drug Businessandleadership.com OPN-305 is a novel proprietary humanized IgG4 monoclonal antibody (MAb) against toll-like receptor 2 (TLR2), a target within the innate immune system, and is under development as a treatment for the prevention of DGF following renal transplantation. |
